Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Scientific Marks Progress On Regulatory, Restructuring Efforts

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific expects FDA to lift restrictions stemming from a two-year-old corporate warning letter by mid-year following the agency's recent commencement of manufacturing site inspections, the company says

You may also be interested in...



Boston Scientific Plans 2008 Post-Warning Letter Interventional Launches

Boston Scientific plans to launch four new interventional cardiology products in 2008 after resolving a two-and-a-half-year-old company-wide FDA warning letter

Boston Scientific Plans 2008 Post-Warning Letter Interventional Launches

Boston Scientific plans to launch four new interventional cardiology products in 2008 after resolving a two-and-a-half-year-old company-wide FDA warning letter

Boston Scientific’s Taxus Liberte

Second-generation paclitaxel-eluting coronary stent system gets FDA "approvable" letter. Boston Scientific plans to launch the device soon after FDA lifts restrictions imposed by a 2006 corporate warning letter citing quality system violations. FDA is re-inspecting the firm's manufacturing facilities and the company expects the restrictions to be lifted around mid-year (1"The Gray Sheet" Feb. 11, 2008, p. 11)

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025744

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel